Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery

Adeno-associated viral (AAV) vectors have emerged as the leading gene delivery platform for gene therapy and vaccination. Three AAV-based gene therapy drugs, Glybera, LUXTURNA, and ZOLGENSMA were approved between 2012–2019 by the European Medicines Agency and the United States Food and Drug Administ...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Pharmacol Ther
Main Authors: Nidetz, Natalie F., McGee, Michael C., Tse, Longping V., Li, Chengwen, Cong, Le, Li, Yunxing, Huang, Weishan
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980784/
https://ncbi.nlm.nih.gov/pubmed/31836454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2019.107453
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki